Get the Stockscreener App
2.25
4.66%
-0.11
Pre-market:
2.28
0.03
+1.33%
Spero Therapeutics Inc stock is traded at $2.25, with a volume of 810.21K.
It is down -4.66% in the last 24 hours and up +15.98% over the past month.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$2.36
Open:
$2.38
24h Volume:
810.21K
Relative Volume:
1.44
Market Cap:
$126.62M
Revenue:
$76.19M
Net Income/Loss:
$-1.61M
P/E Ratio:
225.00
EPS:
0.01
Net Cash Flow:
$28.98M
1W Performance:
+9.76%
1M Performance:
+15.98%
6M Performance:
+289.61%
1Y Performance:
+81.45%
1-Day Range:
$2.25
$2.41
1-Week Range:
$2.02
$2.42
52-Week Range:
$0.5052
$3.22
Spero Therapeutics Inc Stock (SPRO) Company Profile
Name
Spero Therapeutics Inc
Sector
Industry
Phone
857-242-1600
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Compare SPRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRO
Spero Therapeutics Inc
|
2.25 | 132.81M | 76.19M | -1.61M | 28.98M | 0.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-23-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-01-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-22-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Initiated | Evercore ISI | Outperform |
| Nov-05-19 | Reiterated | H.C. Wainwright | Buy |
| Sep-09-19 | Initiated | Janney | Buy |
| Feb-09-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-27-17 | Initiated | BofA/Merrill | Neutral |
| Nov-27-17 | Initiated | Oppenheimer | Outperform |
| Nov-27-17 | Initiated | Stifel | Buy |
View All
Spero Therapeutics Inc Stock (SPRO) Latest News
Is Spero Therapeutics Inc. (2HA) stock positioned for digital growth eraMarket Risk Analysis & Weekly High Potential Stock Alerts - newser.com
Key resistance and support levels for Spero Therapeutics Inc.Portfolio Gains Report & Stock Timing and Entry Methods - newser.com
Sector ETF performance correlation with Spero Therapeutics Inc.July 2025 Reactions & Consistent Income Trade Recommendations - newser.com
Best Momentum Stock to Buy for October 10th - sharewise.com
Spero Therapeutics' (SPRO) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
What analysts say about Spero Therapeutics Inc stockSell Signals and Alerts & Breakthrough Investment Results - earlytimes.in
Spero Therapeutics (NASDAQ:SPRO) Rating Increased to Strong-Buy at Zacks Research - MarketBeat
October 2025's Promising Penny Stocks To Consider - simplywall.st
Key metrics from Spero Therapeutics Inc.’s quarterly dataWall Street Watch & Low Risk High Reward Ideas - newser.com
How strong is Spero Therapeutics Inc. stock revenue growth2025 Biggest Moves & AI Driven Stock Reports - newser.com
Heatmap analysis for Spero Therapeutics Inc. and competitors2025 Institutional Moves & Weekly Breakout Watchlists - newser.com
Is Spero Therapeutics Inc. (2HA) stock safe for risk averse investors2025 Short Interest & Risk Adjusted Swing Trade Ideas - newser.com
Spero Therapeutics, Inc. (NASDAQ:SPRO) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Will Spero Therapeutics Inc. see short term momentumTrade Analysis Report & Daily Volume Surge Signals - newser.com
Spero Therapeutics CEO sells shares worth $121,159 - MSN
Spero Therapeutics Inc. stock trend forecastJuly 2025 Levels & Real-Time Chart Breakout Alerts - newser.com
Is Spero Therapeutics Inc a good long term investmentProtective Put Strategies & Amplify Gains With Picks - earlytimes.in
Spero Therapeutics Inc Stock (SPRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spero Therapeutics Inc Stock (SPRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Keutzer Timothy | Chief Operating Officer |
Aug 28 '25 |
Sale |
1.97 |
1,695 |
3,339 |
739,744 |
| Keutzer Timothy | Chief Operating Officer |
Feb 05 '25 |
Sale |
0.78 |
56,537 |
44,099 |
741,439 |
| Rajavelu Esther | CFO & CBO |
Feb 05 '25 |
Sale |
0.78 |
20,689 |
16,137 |
724,720 |
| Shukla Sath | CEO & President |
Feb 05 '25 |
Sale |
0.78 |
155,333 |
121,160 |
1,736,883 |
| Mahadevia Ankit | Director |
Feb 05 '25 |
Sale |
0.78 |
69,219 |
53,991 |
689,866 |
| Rajavelu Esther | CFO & CBO |
Nov 07 '24 |
Sale |
1.31 |
23,351 |
30,590 |
396,515 |
| Rajavelu Esther | CFO & CBO |
Nov 08 '24 |
Sale |
1.30 |
17,245 |
22,418 |
379,270 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):